Idera Pharma (IDRA) Updates on IMO-2125 Phase 1/2 in Metastatic Melanoma; Promising Data Noted
- Wall St. edges higher, supported by banks, telecoms
- Equinix (EQIX) Announces $3.6B Acquisition of Data Center Portfolio from Verzion (VZ)
- Deal Progress Said to Slow as Johnson & Johnson (JNJ) Puts Actelion (ALIOY) Under Microscope - Source
- Trump Wants to Cancel New Air Force One Order with Boeing (BA)
- Roper Industries (ROP) to acquire Deltek in $2.8B Deal
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) is reporting initial clinical data from its ongoing Phase 1/2 clinical trial of intra-tumoral IMO-2125, a Toll-like receptor (TLR) 9 agonist. In this arm of the Phase 1 portion of the trial, IMO-2125 is being evaluated in combination with ipilimumab for treatment of patients with metastatic melanoma who have failed prior PD-1 therapy. These early results indicate that IMO-2125 is demonstrating promising clinical activity and is being well tolerated in a patient population with minimal options and low expectation of clinical response with ipilimumab treatment alone. Further clinical information from the ongoing dose escalation portion of the trial, as well as detailed information on the translational results, will be presented during an oral session at the 2016 Society for Immunotherapy of Cancer Annual Meeting beginning November 9th in Maryland.
“We have completed extensive pre-clinical work in a broad scope of tumor types to test the hypothesis of intra-tumoral administration of IMO-2125 inducing a meaningful effect on the tumor microenvironment and potentiating local and systemic tumor regression in patients. This work gave us confidence to test the ability of IMO-2125, beginning with this current study in PD-1 refractory metastatic melanoma patients,” stated Vincent Milano, Idera’s Chief Executive Officer.
“We are energized by the early results from this ongoing trial and have been solidifying our plans to accelerate the program as we believe there is a clear path to bring IMO-2125 to melanoma patients who have not benefited from checkpoint inhibition alone and open an opportunity to establish IMO-2125 as the agent of choice to activate the tumor microenvironment and potentially improve outcomes for patients,” Milano added. “Following a full strategic review, we have decided to prioritize the IMO-2125 program and explore strategic options for IMO-8400 in B-cell lymphoma.”
Current Data Analysis
- 10 patients in 3 dosing cohorts (4mg, 8mg and 16mg) have been dosed and are assessable for safety, as of the September 19, 2016 cutoff date;
- IMO-2125 in combination with ipilimumab is being generally well tolerated at all 3 dose levels studied to date;
- Immune related adverse events have been observed in 3 subjects: 2 responding patients have experienced hypophysitis and 1 patient has discontinued the study due to a recurrence of immune related hepatitis previously observed on prior therapy with ipilimumab;
- No dose limiting toxicities (DLTs) have been identified to date and the study is currently enrolling at the highest (32mg) dosing cohort in combination with ipilimumab.
- 6 patients treated in the first 2 dosing cohorts (4mg and 8mg) are assessable for initial clinical activity, as of the September 19, 2016 cutoff date;
- 3 of the 4 patients with cutaneous melanoma are responders with one Complete Response (CR) and 2 Partial Responses (PR);
- 2 patients with mucosal melanoma experienced Progressive Disease (PD).
- Translational data seen through the first two dosing cohorts is promising relative to the induction of immune responses;
- Detailed information on the translational findings from biopsies taken in the first 2 dosing cohorts and the relationship of these to clinical response is the subject of an accepted oral presentation on November 11, 2016 at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting by Cara Haymaker, Ph.D., University of Texas, MD Anderson Cancer Center.
“The degree of activity we’ve seen so far in this trial is very exciting as these patients are very unlikely to respond to other therapies. All three responses that we’ve seen are clinically meaningful, and these patients continue to do well following treatment,” stated Adi Diab, M.D., Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center.
These early results are from the Phase 1 portion of study IMO-2125-204 (NCT02644967) in which cohorts of patients with metastatic melanoma unresponsive to PD-1 inhibitor therapy are being administered escalating doses of IMO-2125 ranging from 4 mg/kg through 32 mg/kg. IMO-2125 is injected intra-tumorally into a designated tumor lesion together with a standard dosing regimen of ipilimumab given intravenously. Following determination of the recommended Phase 2 dose (RP2D) additional patients will be treated in an expansion Phase 2 portion of the study. The primary objective of the Phase 1 portion of the trial is to characterize the safety and determine a RP2D of IMO-2125 when administered intra-tumorally in combination with ipilimumab. The primary objective of the Phase 2 portion is to assess the clinical activity of IMO-2125 in combination with ipilimumab at the respective RP2D in patients. Assessment will be based on the immune-related response criteria (irRC) and additionally the traditional RECIST criteria. Serial biopsies are being taken of selected injected and non-injected tumor lesions to assess immune changes and correlate with clinical response assessments. The trial will enroll approximately 60 patients. The study is being conducted at The University of Texas MD Anderson Cancer Center and is being led by Adi Diab, M.D., Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson as part of a strategic research alliance announced by Idera and MD Anderson in 2015.
Business UpdateIdera is also reporting that the company has chosen to suspend the clinical development of IMO-8400 for B-cell lymphomas, including studies in Waldenstroms Macroglobulinemia (WM) and Diffuse Large B-Cell Lymphoma (DLBCL), and will explore strategic options in these indications. This decision was based upon the prioritization of the clinical development plans for IMO-2125 and our assessment that the level of clinical activity seen in the WM trial does not support monotherapy, the very slow enrollment rate in DLBCL and our commercial assessment. No safety concerns have been observed with IMO-8400 in the B-cell Lymphoma program. The development of IMO-8400 in dermatomyositis continues and is not impacted by this decision.
Investor Event and WebcastIdera will host a conference call and live webcast on Monday, September 26 at 9:00 A.M. EST to review the data being presented along with a discussion of the next steps for the IMO-2125 development program in melanoma. To participate in the conference call, please dial (844) 882-7837 (domestic) and (574) 990-9824 (international). The webcast can be accessed live or in archived form in the “Investor’s” section of the company’s website at www.iderapharma.com. The company has also posted a slide presentation to the Idera corporate website in the “Investors” section which will be referenced during the conference call. Additionally the company has updated its corporate presentation which has also been posted to the Idera corporate website in the “Investors” section.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kadmon (KDMN) Issues Encouraging Update on Tesevatinib Phase 2 in NSCLC
- Janssen Announces Encouraging Data from IMBRUVICA Phase 2 in cGVHD
- CTI BioPharma (CTIC) Presents Statistically Significant Data from PERSIST-2 at ASH 2016
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!